Under the agreement, both partners will contribute equally, with a 50:50 shareholding structure. Morepen Medipath will indirectly hold a 30% stake in the proposed joint venture. Shares of Morepen Laboratories Ltd ended at ₹49.15, down by ₹0.16, or 0.16%, on the BSE.
